ibandronic acid has been researched along with Fracture, Pathologic in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciornohac, JF; Mathonet, PY; Willems, S | 1 |
| Ohashi, S; Ono, K; Tanaka, S | 1 |
| Hagino, H; Hashimoto, J; Katagiri, H; Okano, T | 1 |
| Okazaki, R | 1 |
| Bilezikian, JP | 1 |
| Bruyère, O; Hiligsmann, M; Neuprez, A; Reginster, JY | 1 |
| Airia, P; Borisova, N; Ferko, NC; Grima, DT; Thompson, MF | 1 |
| Biskobing, DM; Downs, R; Novy, AM | 1 |
| McClung, M | 1 |
| Fassbender, WJ; Stumpf, UC | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
7 review(s) available for ibandronic acid and Fracture, Pathologic
| Article | Year |
|---|---|
[Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Denosumab; Diphosphonates; Drug Therapy, Combination; Fractures, Spontaneous; Humans; Ibandronic Acid; Molecular Targeted Therapy; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide | 2014 |
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
Novel therapeutic options for osteoporosis.
Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid | 2002 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2003 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
5 other study(ies) available for ibandronic acid and Fracture, Pathologic
| Article | Year |
|---|---|
[Subtrochanteric pathological fracture on bisphosphonates].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Hip Fractures; Humans; Ibandronic Acid | 2018 |
[Anti-fracture efficacy of intravenous ibandronate: how to translate epidemiological studies into daily clinical practice].
Topics: Bone Density Conservation Agents; Clinical Medicine; Diphosphonates; Fractures, Spontaneous; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis | 2009 |
How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
Topics: Bone Density Conservation Agents; Cost Sharing; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Markov Chains; Middle Aged; Osteoporosis; Reimbursement Mechanisms; Risedronic Acid | 2012 |
[Monthly tablet in postmenopausal osteoporosis].
Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal | 2005 |
[DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Minimally Invasive Surgical Procedures; Organometallic Compounds; Osteoporosis; Parathyroid Hormone; Peptide Fragments; Recombinant Proteins; Spinal Fractures; Teriparatide; Thiophenes | 2006 |